ACN: 133 809 382
Mullaways Medical Cannabis Pty Ltd, an Australian Company, has developed a natural low dose cannabinoid-derived medicine for the treatment of chronic pain which is involved in a range of conditions including endocannabinoid imbalance, severe uncontrolled epilepsy, cancer treatment, multiple sclerosis, diabetes, terminal illnesses and Crohn's disease. Mullaways Medical Cannabis has cross-bred different types of the plant to produce new strains that could be used to develop cannabinoid medicines to treat a wide range of disorders.

The first of these 'Super breeds' of medicinal cannabinoids developed in Australia, called the Cleverman will be registered with IP Australia who administer Plant Breeder's Rights.

Research Leader and Director Anthony David Bower said, "It has been demonstrated that there are something like 80 cannabinoids in the cannabis plant, and to date only a small number have been looked at in any detail."

Mullaways Medical Cannabis proposes to research and develop other cannabinoid based medicines including patches, creams, oils and edibles that have therapeutic benefits and that may be delivered more safely and effectively than by smoking cannabis.

The company also proposes to conduct research into the different methods of growing the cannabis plant and conduct research into the basic chemistry and pharmacology of cannabinoids with the aim of developing cannabinoid based medicines of an acceptable standard that may be delivered more safely and effectively than by smoking cannabis.

Safe THC/Cannabinoid Medicines

  • The Research by Mullaways Medical Cannabis has already led to groundbreaking Science in the field of Medical Cannabis and results of this Cannabinoid Research will soon be Published. The Research opens the way for effective Medical Cannabinoid Dosage. Based on safe levels of Cannabinoid/THCA/THC consumption Mullaway's has developed easy to use Tables showing the SAFE allowable use of THCA/THC.
  • This is a major breakthrough for Research into Cannabinoid Treatments. SAFE Cannabinoid Treatment Plans (for Cancer Patients for example) can now be worked out to help with the disease or symptoms. Tolerance levels can be adjusted so the Psychotropic Effect is not over whelming but manageable or pleasurable.
  • This Research has removed the demon from the Psychotropic Effect and shows that it is a most valuable Medical Tool. The Research highlights the Psychotropic Effect is very much a pleasurable experience under most circumstances and even if large doses of Cannabinoids are required for a particular Treatment this can be easily managed.
  • The Research by Mullaways Medical Cannabis has made it possible for the first time to; Design, Cultivate, Trial and Evaluate Cannabinoid Treatments using SAFE Doses of Cannabinoids/THCA/THC. While the rest of the Medical Cannabis Research world tries to genetically engineer Cannabis without any THC or tries to produce a rich Blend of Cannabinoids/THC from low THC Cannabis Mullaway's Research has already produced the Jewel in the Crown of Medical Cannabis Research.
  • Extracts from
    Hemp Foods and THC Levels:
    A Scientific Assessment

    by Franjo Grotenhermen, M.D., Michael Karus, and Daike Lohmeyer

    3.3 Influence of physical factors on THC content

  • Ninety-five precent of the THC present in the Cannabis plant is found in a pharmacologically inactive form, i.e. one of two delta-9-tetrahydrocannabinolic acids (THCA) (Turner 1980), while the majority of biological effects are caused by the corresponding neutral phenolic forms of THC (Dewey 1986)......
  • Baker et al. (1981) analyzed 64 marijuana samples (Cannabis herb) and 26 hashish samples (Cannabis resin) for their relative amounts of THCA and THC, and found a wide range of ratios, especially in marijuana. In Cannabis resin, the ratio ranged between 0.5 to 1 and 6.1 to 1.
  • 4 THC thresholds for psychotropic effects

  • Some experimental and clinical studies report experiences with threshold values for psychotropic THC doses. Acute effects below the psychotropic threshold cannot be distinguished from placebo effects.
  • ...... A single dose of 5 mg THC can be regarded as a placebo dose. In various clinical studies, psychotropic reactions were also observed following single doses of 5 mg THC. However, these cannot be distinguished from effects that occur after administration of placebos. As the duration of action of THC in therapeutic dosage ranges between 4 and 12 hours, a daily intake of 2 x 5 mg which equals 10 mg THC, administered orally in a lipophilic carrier, will not have any effects that could be distinguished from placebo effects.
  • Zero Tolerance of Pain & Suffering

    Scientific matters can only be clarified by prolonged, faithful bona fide observations in friendly exchange of opinion, never by
    imprisonment. A person's right to know, to learn, to inquire, to make bona fide errors, to investigate must, by all means, be safe,
    if the word FREEDOM should ever be more than an empty political slogan.

    2013 NSW Government Inquiry
    into the use of cannabis for medical purposes.

    The Inquiry will examine the efficacy and safety of using cannabis for medical purposes; if and how cannabis should be supplied for medical use; the legal implications and issues concerning the use of cannabis for medical purposes and any other related matters. The Inquiry will examine a range of modes by which the chemical properties of cannabis may be accessed for therapeutic purposes, from smoking of the plant to the manufacturing of pharmaceutical products consumed in nasal sprays, tablet or other forms.

  • Use of cannabis for medical purposes (Inquiry)
  • Submissions to the Inquiry
  • Submission from Mullaways
  • Submission from Dr Ian Webster AO
  • Cannabis and chronic pain: the poor man's analgesic
  • Public Hearing 1 Transcript 11 March 2013
  • Mullaways on Pages 31 to 39 of Transcript
  • Public Hearing 2 Transcript 18 March 2013
  • Executive Summary & Recommendations
  • Full Report
  • NSW Government Response
  • Cannabinoids In Health

    In 1988 the first cannabinoid receptor was discovered and since then researchers have learned that there are two different types of cannabinoid receptors which are distributed throughout our bodies and that we make chemicals within our bodies endocannabinoids which are similar to the cannabinoids in the cannabis plant. Both plant and human cannabinoids bind to and influence these receptors in order to discourage the rise and progression of numerous disease processes.

    Cannabinoid receptor type-1 (CB1) - CB1 receptors are found primarily in the brain, to be specific in the basal ganglia and in the limbic system, including the hippocampus. They are also found in the cerebellum and in both male and female reproductive systems. CB1 receptors are absent in the medulla oblongata, the part of the brain stem responsible for respiratory and cardiovascular functions. Thus, there is not the risk of respiratory or cardiovascular failure that can be produced by some drugs. CB1 receptors appear to be responsible for the euphoric and anticonvulsive effects of cannabis.

    Cannabinoid receptor type-2 (CB2) - CB2 receptors are predominantly found in the immune system, or immune-derived cells with the greatest density in the spleen. While found only in the peripheral nervous system, a report does indicate that CB2 is expressed by a subpopulation of microglia in the human cerebellum. CB2 receptors appear to be responsible for the anti-inflammatory and possibly other therapeutic effects of cannabis.

    The cannabinoid system is a major neurochemical system whose functional significance has only recently been explored. We are witnessing the beginning of a revolution in cannabinoid research.

    The endogenous opioid system and the endocannabinoid system are co-localised in pain-processing regions and opioids and cannabinoids exert a synergistic antinociceptive effect. The ability of cannabinoids to induce antinociception in virtually every animal model of acute or persistent pain evaluated has encouraged researchers to try to better understand this important non-opioid system of analgesia.

    There are currently around 80 known/discovered types of cannabinoids. In 2005 research from the University of Mississippi, USA showed cannabis contains 489 identifiable chemical compounds known to exist in the cannabis plant. At least 200 of these are cannabinoids, terpenes and flavonoids which are found in a wide range of concentrations within the flower, leaf, and stem, and which are the basis for medical and scientific use of cannabis. The cannabinoids can serve as appetite stimulants, antiemetics, antispasmodics, and have some analgesic effects.

    At least 1 in 5 Australians, that's including children, live with chronic pain. Among people aged over 65, it's 1 in 3. Research shows that chronic pain left untreated leads to devastating effects on the welfare of people's lives, and the longer this goes on untreated the worse it gets. The National Pain Strategy, developed by more than 150 healthcare professionals and consumers at a 2010 national summit, recommended chronic pain be recognised as a priority health issue and constitute a disease in its own right. Yet it remains one of the most neglected areas of healthcare.

    Rare disease affects more than 2 million Australians and are defined as a condition, syndrome or disorder that affects 1 in 10,000 people or less and are either life-threatening or chronically debilitating. Many are alone in their plight to tackle and come to terms with an incredibly unique, debilitating and life-threatening illness.